ライフサイエンスコーパス: PAP

1 PAP activity was stimulated by anionic lipids (cardiolip

2 PAP binds to VPg with high affinity (29.5 nm); the react

3 PAP can be classified into different types on the basis

4 PAP has a prevalence of at least 7 cases per million ind

5 PAP I competes with the 3' -> 5' exonucleases for pre-tR

6 PAP is also a cap-binding protein and is a potent antivi

7 PAP levels were specifically elevated in the cytosol of

8 PAP results in progressive dyspnoea of insidious onset,

9 PAP seems to have contributed to the death of only 1 pat

10 PAP(248-286) is a peptide fragment of prostatic acid pho

11 PAP-specific CD8(+)CTLA-4(+) T cells also suppressed T c

12 PAP-specific T cells were detected in both cohorts, incl

13 can be rescued by the expression of lipin-1 PAP activity or by inhibition of ERK signaling.

14 e, we investigate the requirement of lipin-1 PAP versus coactivator function in the establishment of

15 ry fatty acids into triglycerides, lipin 2/3 PAP activity has a critical role in phospholipid homeost

16 ular function has been unknown, confers ~30% PAP activity of wild type cells.

17 SIGNIFICANCE: Identification of App1p as a PAP enzyme will facilitate the understanding of its cell

18 culate a PAP/CO slope, and exPH defined as a PAP/CO slope >3 mm Hg/l/min.

19 diac output (CO) measurements to calculate a PAP/CO slope, and exPH defined as a PAP/CO slope >3 mm H

20 P(248-286), could instead be attributed to a PAP(248-286)/lipid coaggregate.

21 57 years, 59% women), 296 (41%) had abnormal PAP/CO slopes.

22 The association of abnormal PAP/CO slope with outcomes remained significant after ex

23 Individuals with abnormal PAP/CO slope had a 2-fold increased hazard of future CV

24 d then collapsed into three groups (LEP, ACN/PAP, and MIP/SOL).

25 MIP/SOL patients (but not ACN/PAP) derived DFS and SDFS but not OS benefit from ACT (O

26 e worse for MIP/SOL compared with LEP or ACN/PAP subgroup (P < .01); this remained marginally signifi

27 PNP), o-nitrophenol (ONP), or p-aminophenol (PAP) as products.

28 detection limit of 31 muM for p-aminophenol (PAP) using Pt electrodes and was also used to detect enz

29 G to an electroactive species p-aminophenol (PAP) which could be monitored on an electrode.

30 We find that in addition to forming amyloid, PAP(248-286) much more readily assembles with lipid vesi

31 ively describe PAP depurination activity and PAP-VPg interactions.

32 ids), PAPS consumption (in the cytosol), and PAP (the stress signaling molecule 3'-phosphoadenosine 5

33 ogether, our results reveal a PAS-guided and PAP-mediated paradigm for gene expression in response to

34 -CSF signaling in surfactant homeostasis and PAP pathogenesis in humans and have therapeutic implicat

35 ochemically active substrates, PNP, ONP, and PAP were determined to be 1.1, 2.8, and 0.5 muM, respect

36 ganellar transport systems for both PAPS and PAP.

37 undergo outpatient diagnostic procedures and PAP titration in the sleep laboratory (ideally within 2-

38 d 3T3-L1 cells where total lipin protein and PAP activity levels are down-regulated by the combined d

39 saccharide and bacteremia but not of TAT and PAP.

40 n [TAT]), fibrinolysis (plasmin-antiplasmin [PAP]), and complement (C3b, C5a, C5b-9) in baboons infus

41 App1p PAP was purified from yeast and characterized with respe

42 Instead, App1p PAP is thought to play a role in endocytosis because its

43 ld-type cells, are rapidly polyadenylated as PAP I levels increase, leading to dramatic reductions in

44 lipid synthesis and composition, as well as PAP activity in various PAP mutant strains, showed the e

45 These cases need not have associated PAP.

46 Autoimmune PAP accounts for >90% of all cases.

47 prevalent clinical form of PAP is autoimmune PAP (aPAP) whereby IgG autoantibodies neutralize GM-CSF.

48 To date, all the available PAP structures are from the PAPalpha clade.

49 rgets various RNAs, the interactions between PAP and turnip mosaic virus genome-linked protein (VPg)

50 We propose that there is a link between PAP/SAL pathway, ethylene signaling and Fe metabolism.

51 There is a link between PAP/SAL retrograde pathway, ethylene signaling and Fe me

52 h minimal overlap in samples with borderline PAP-AUC.

53 ing a double mutant mouse deficient for both PAP synthesis and hydrolysis, consistent with a mechanis

54 Here, we show that fibril formation by PAP(248-286) is accelerated dramatically in the presence

55 pecific SP components on fibril formation by PAP(248-286) revealed that this effect is primarily due

56 required for normal mRNA polyadenylation by PAP I.

57 The diacylglycerol produced by PAP is used for the synthesis of triacylglycerol as well

58 suggest that the polyadenylation of tRNAs by PAP I likely proceeds in a distributive fashion unlike w

59 Star-PAP specificity and may block canonical PAP activity toward BIK mRNA.

60 differ among the various diseases that cause PAP.Conclusions: This insight into the alveolar lipidome

61 Strongly increased cellular PAP levels negatively affect plant growth, as observed i

62 In the yeast Saccharomyces cerevisiae, PAP is encoded by PAH1, DPP1, and LPP1.

63 arious underlying conditions; and congenital PAP is caused by mutations in genes involved in surfacta

64 ation analysis profile-area under the curve (PAP-AUC) of consecutive methicillin-resistant Staphyloco

65 tance of sulfur assimilation and cytoplasmic PAP hydrolysis to normal liver function.

66 nity of PARylated PAP in vitro and decreased PAP association with non-heat shock protein-encoding gen

67 d in vitro disease model of CSF2RA-deficient PAP, and introduce gene-corrected iPSC-derived monocytes

68 ylglycerol, is unique among Mg(2+)-dependent PAP enzymes in that its reaction is not involved with de

69 hniques were used to quantitatively describe PAP depurination activity and PAP-VPg interactions.

70 P1, LPP1) are responsible for all detectable PAP activity in yeast.

71 CSF-specific autoantibody and do not develop PAP.

72 We have diagnosed PAP among patients with ADA deficiency more commonly in

73 per 10 mm Hg increase; P = 0.022), diastolic PAP - pulmonary capillary wedge pressure (HR, 2.19; 95%

74 per 10 mm Hg increase; P = 0.027), diastolic PAP (HR, 1.83; 95% CI, 1.09-3.08 per 10 mm Hg increase;

75 tolic pulmonary pressure gradient (diastolic PAP minus mean PAWP) <7 mm Hg, a transpulmonary pressure

76 ss of PAP activity, indicating that distinct PAP enzymes in S. cerevisiae are encoded by APP1, PAH1,

77 nce as the primary macrophage defect driving PAP pathogenesis, and support the feasibility of transla

78 ease in hepatic lipin-1 protein and elevated PAP activity, which maintained lipid homeostasis under b

79 ur genes (APP1, DPP1, LPP1, and PAH1) encode PAP activity in yeast, and it has been unclear which gen

80 ata suggest that in the in vivo environment, PAP(248-286) is likely to form fibrils efficiently, thus

81 These data establish PAP-iPSC-derived monocytes and macrophages as a valid in

82 participant received a vaginal examination, PAP smear, and completed a questionnaire.

83 res its RNA binding and, to a lesser extent, PAP-stimulatory functions.

84 derstand how the N-Lip and C-Lip combine for PAP function, we determined crystal structures of Tetrah

85 s meets the requirements for new methods for PAP detection and can be used in future feed authenticat

86 andardize and may reduce the requirement for PAP-AUC confirmation.

87 Our data suggest a more dynamic role for PAP I in maintaining functional tRNA levels in the cell.

88 s and lead to new therapeutic strategies for PAP.

89 tRNAs, which are normally not substrates for PAP I in wild-type cells, are rapidly polyadenylated as

90 ured RNA derived from tobacco etch virus for PAP binding.

91 ns (lipin 1, lipin 2, and lipin 3) each have PAP activity, but have distinct tissue distributions, wi

92 iPS cells from two children with hereditary PAP (hPAP) caused by recessive CSF2RA(R217X) mutations a

93 ow that human RegIIIalpha (also known as HIP/PAP) binds membrane phospholipids and kills bacteria by

94 m of RNA depurination, and to understand how PAP recognizes and targets various RNAs, the interaction

95 turation, compete with poly(A) polymerase I (PAP I) for tRNA precursors in wild-type cells.

96 of polyadenylation by poly(A) polymerase I (PAP I) in Escherichia coli leads to toxicity and cell de

97 n of some pre-tRNAs by poly(A) polymerase I (PAP I), which exacerbates inviability.

98 dosome is required for poly(A) polymerase I (PAP I)-dependent polyadenylation after Rho-independent t

99 t studies suggest that poly(A) polymerase I (PAP I)-mediated polyadenylation in Escherichia coli is h

100 predominant HRCT presentation of idiopathic PAP was interlobular septal thickening and ground glass

101 ted tomography (HRCT) features of idiopathic PAP.

102 e: 38+/-14years; 54.3% male) with idiopathic PAP (proved by bronchoalveolar lavage or biopsy) were re

103 Delta mutant exhibited a 10-fold increase in PAP activity.

104 es suggest that exercise-induced increase in PAP to a mean higher than 30 mm Hg may be associated wit

105 to the proapoptotic environment observed in PAP.

106 sis of Arabidopsis thaliana mutant plants in PAP-SAL1 pathway revealed that the ferritin genes AtFER1

107 macrophages and reduced disease severity in PAP mice.

108 the Kv1.3-specific small-molecule inhibitor PAP-1, thus highlighting the importance of Kv1.3 in neur

109 )ation (PARylation) in vitro, which inhibits PAP activity.

110 iated phosphorylation of Pah1p inhibited its PAP activity by decreasing catalytic efficiency, and the

111 nown about the biochemical regulation of its PAP activity.

112 a role in vesicular trafficking through its PAP activity.

113 ssion of a truncated lipin 1 protein lacking PAP activity but retaining transcriptional regulatory fu

114 Even at ~50-fold lower PAP(248-286) concentrations, messicles form at least 10-

115 Maximum PAP activity was dependent on Triton X-100 (20 mm), PA (

116 Mean PAP was a predictor of mean RV E(LL) (beta = .19, P = .0

117 associated with increased RV afterload (mean PAP and PVRI).

118 The average mean PAP increased from baseline (20.2 mm Hg) to followup (24

119 tients in this study, 86 had borderline mean PAP (21-24 mm Hg) at baseline.

120 Our findings indicate that borderline mean PAP and an elevated TPG in patients with SSc predict pro

121 Patients with borderline mean PAP were more likely to develop PH than patients with me

122 Hg, a transpulmonary pressure gradient (mean PAP minus mean PAWP) <12 mm Hg, and pulmonary vascular r

123 L) positively correlated with increased mean PAP (r = 0.5, P = .03) and septal eccentricity index (r

124 ere independently related to mortality: mean PAP (hazard ratio [HR], 1.61; 95% confidence interval [C

125 A combination of mean PAP and mean PAWP defines postcapillary PH.

126 ean RV E(LL) positively correlated with mean PAP (r = 0.62, P < .0014) and pulmonary vascular resista

127 likely to develop PH than patients with mean PAP</=20 mm Hg (P<0.001 by log rank test, hazard ratio [

128 Loss of lipin 1-mediated PAP activity in adipocytes led to reduced glyceride synt

129 a suggest that mice lacking lipin 1-mediated PAP activity in skeletal muscle may serve as a model for

130 nd inhibited its association with membranes, PAP activity, and triacylglycerol synthesis.

131 nsion was ascertained using minute-by-minute PAP and cardiac output (CO) measurements to calculate a

132 PARP1 binds to and modifies PAP by poly(ADP-ribosyl)ation (PARylation) in vitro, whi

133 ly(ADP-ribose) polymerase 1 (PARP1) modifies PAP and regulates its activity both in vitro and in vivo

134 d in both cohorts, including multifunctional PAP-specific T-helper 1-biased T cells.

135 Multipoint PAP-flow relationships are usually described by a linear

136 macrophages differentiated from noncorrected PAP-iPSCs exhibited distinct defects in GM-CSF-dependent

137 ur understanding of the organelle-to-nucleus PAP retrograde signaling pathway.

138 The absence of PAP I led to improved aminoacylation of 5'-immature tRNA

139 cted prior to immunization in the absence of PAP-specific effector responses.

140 of BPNT-1 leads to the toxic accumulation of PAP in yeast and non-neuronal cell types in mice [4, 5].

141 Administration of PAP-1 significantly inhibited neurodegeneration and neur

142 By analysis of PAP activity in mutants lacking each of the proteins, we

143 evealed that PAPST2 mediates the antiport of PAP, PAPS, ATP, and ADP.

144 ce and lung histopathology characteristic of PAP; 2) alveolar macrophages from Rasgrp1-deficient mice

145 The complexity of PAP isoforms suggests that they might play different rol

146 ples and find that they partially consist of PAP fragments, interact with HIV particles and increase

147 nism, in which a critical surface density of PAP(248-286) on liposomes enables peptide-mediated parti

148 Two of the seven later developed evidence of PAP.

149 ere the most frequently observed features of PAP in PGA-treated eyes compared with untreated fellow e

150 Similar findings of PAP were not found among patients with SCID caused by ot

151 The most prevalent clinical form of PAP is autoimmune PAP (aPAP) whereby IgG autoantibodies

152 vities assigned to SEVI, the amyloid form of PAP(248-286), could instead be attributed to a PAP(248-2

153 presents an important organellar importer of PAP, providing a piece of the puzzle in our understandin

154 nd RNase PH, there is a >30-fold increase of PAP I-dependent poly(A) tails that are </=10 nt in lengt

155 Further, VPg is a potent inhibitor of PAP depurination of RNA in wheat germ lysate and compete

156 Multiple isoforms of PAP have been identified in vertebrates, which originate

157 The lack of PAP in the pah1Delta mutant highly elevated PSS activity

158 triple mutant resulted in a complete loss of PAP activity, indicating that distinct PAP enzymes in S.

159 r macrophages that drive the pathogenesis of PAP in more than 90% of patients.

160 and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo.

161 g pioglitazone as a novel pharmacotherapy of PAP.

162 ies should be educated on the possibility of PAP, especially when initiating monocular PGA therapy.

163 The presence of PAP activity in the pah1Delta dpp1Delta lpp1Delta triple

164 The predominant HRCT presentation of PAP was interlobular septal thickening (ILST;100%) and g

165 Here, we study the coassembly process of PAP(248-286), a seminal peptide that displays both amylo

166 tus was significantly improved regardless of PAP level.

167 ore, our data demonstrate that regulation of PAP I is critical not for preventing the decay of mRNAs,

168 The lung pathology was typical of PAP.

169 n combination, showed that Pah1p is the only PAP involved in the synthesis of triacylglycerol as well

170 gatively regulate either membrane binding or PAP activity.

171 also not substrates for RNase T, RNase PH or PAP I.

172 This illustrates mechanisms for lipin/Pah PAP function, membrane association, and lipin-related pa

173 histologic pattern-lepidic (LEP), papillary (PAP), acinar (ACN), micropapillary (MIP), or solid (SOL)

174 ts reduced RNA binding affinity of PARylated PAP in vitro and decreased PAP association with non-heat

175 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidase (NT5E) hydrolyze extracell

176 t semen proteins prostatic acid phosphatase (PAP) and semenogelins form amyloid fibrils in vitro.

177 es lipin-1, a phosphatidic acid phosphatase (PAP) controlling the rate-limiting step in the phospholi

178 The lipin phosphatidic acid phosphatase (PAP) enzymes are required for triacylglycerol (TAG) synt

179 and 3) act as phosphatidic acid phosphatase (PAP) enzymes, which are required for triacylglycerol (TA

180 I-816]) encoding prostatic acid phosphatase (PAP) in patients with recurrent, nonmetastatic prostate

181 Lipin 2 is a phosphatidic acid phosphatase (PAP) responsible for the penultimate step of triglycerid

182 report on human prostatic acid phosphatase (PAP), a tumor marker, with a limit of detection of 11 pM

183 (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).

184 mmalian homolog, prostatic acid phosphatase (PAP; also known as ACPP-201) stably associates with muri

185 rs and a phosphatidic acid (PA) phosphatase (PAP) enzyme that catalyzes a critical step in the synthe

186 Phosphatidate phosphatase (PAP) catalyzes the dephosphorylation of phosphatidate to

187 -1 functions as a phosphatidate phosphatase (PAP) enzyme in the glycerol 3-phosphate pathway for trig

188 The three lipin phosphatidate phosphatase (PAP) enzymes catalyze a step in glycerolipid biosynthesi

189 Mg(2+)-dependent phosphatidate phosphatase (PAP) enzymes with essential roles in lipid biosynthesis.

190 hich functions as phosphatidate phosphatase (PAP) in the yeast Saccharomyces cerevisiae, plays a cruc

191 tes a role of the phosphatidate phosphatase (PAP) in this metabolism; the enzyme produces the diacylg

192 Yeast App1p is a phosphatidate phosphatase (PAP) that associates with endocytic proteins at cortical

193 The PAH1-encoded phosphatidate phosphatase (PAP), which catalyzes the committed step for the synthes

194 avage product of prostatic acid phosphatase, PAP(248-286)).

195 mplex with 3'-phosphoadenosine 5'-phosphate (PAP) alone and together with the Gl sinigrin.

196 olecule is 3'-phosphoadenisine-5'-phosphate (PAP) and it's in vivo levels are regulated by SAL1/FRY1,

197 i-resident 3'-phosphoadenosine 5'-phosphate (PAP) phosphatase (gPAPP) and Bisphosphate 3'-nucleotidas

198 entify the 3'-phosphoadenosine 5'-phosphate (PAP) phosphatase SAL1 as a previously unidentified and c

199 cytosolic 3'-phosphoadenosine 5'-phosphate (PAP), a byproduct of sulfation reactions utilizing the u

200 gnaling by 3'-phosphoadenosine 5'-phosphate (PAP).

201 ing as a phosphatidic acid phosphohydrolase (PAP) enzyme in the triglyceride-synthesis pathway and by

202 Lipin-1 is a phosphatidate phosphohydrolase (PAP) required for the generation of diacylglycerol durin

203 ition of the noncanonical poly(A) polymerase PAP-associated domain-containing 5 (PAPD5) increased TER

204 the catalytic module of poly(A) polymerase (PAP) are recruited by the CPSF30-hFip1 complex in vitro,

205 lation of nascent RNA by poly(A) polymerase (PAP) is important for 3' end maturation of almost all eu

206 Poly(A) polymerase (PAP) is the enzyme that catalyzes the poly(A) addition r

207 the nuclear noncanonical poly(A) polymerase (PAP) speckle targeted PIPKIalpha regulated PAP (Star-PAP

208 a nuclear non-canonical poly(A) polymerase (PAP) that shows specificity toward mRNA targets.

209 Poly(A) polymerase (PAP), the enzyme that catalyzes the formation of the tai

210 ing protein, PABPN1, and poly(A) polymerase (PAP).

211 ibutions, with lipin 1 being the predominant PAP enzyme in many metabolic tissues.

212 s with OHS receive positive airway pressure (PAP), 3) continuous positive airway pressure (CPAP) rath

213 mic parameters [pulsatile arterial pressure (PAP) and heart rate (HR)].

214 Abnormal pulmonary arterial pressure (PAP) responses to exercise have been described in select

215 s defined as mean pulmonary artery pressure (PAP) >/= 25 mm Hg.

216 rements of a mean pulmonary artery pressure (PAP) >/=25 mm Hg and mean wedged PAP (PAWP) >15 mm Hg.

217 was found between pulmonary artery pressure (PAP) and AF in these patients, right ventricular functio

218 rease of pulmonary capillary wedge pressure, PAP and RAP were more pronounced in AF than in SR, sugge

219 basis of the pathogenetic mechanism: primary PAP is characterized by the disruption of granulocyte-ma

220 Pokeweed antiviral protein (PAP) from Phytolacca americana is a ribosome-inactivatin

221 Pulmonary alveolar proteinosis (PAP) is a rare lung syndrome caused by the accumulation

222 Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by the accumulation of

223 Rationale: Pulmonary alveolar proteinosis (PAP) is characterized by filling of the alveolar spaces

224 atients with pulmonary alveolar proteinosis (PAP) syndrome, disruption of granulocyte/macrophage colo

225 teristic for pulmonary alveolar proteinosis (PAP), it is not specific and has not been compared betwe

226 ption causes pulmonary alveolar proteinosis (PAP), we evaluated lipid composition in alveolar macroph

227 re secondary pulmonary alveolar proteinosis (PAP).

228 er developed pulmonary alveolar proteinosis (PAP).

229 We purified PAP from the pah1Delta dpp1Delta lpp1Delta triple mutant

230 (PAP) speckle targeted PIPKIalpha regulated PAP (Star-PAP) controls E6 mRNA polyadenylation and expr

231 nhibition of either CTLA-4 or IL-35 reversed PAP-specific suppression of tvDTH response.

232 s capable of quantifying 0.1% (w/w) ruminant PAP in feed in a tissue- and species-specific way.

233 ncoding GM-CSF receptor subunits); secondary PAP results from various underlying conditions; and cong

234 One patient had severe PAP after long-term unilateral PGA exposure.

235 Patient-specific PAP-iPSCs were generated from CD34(+) bone marrow cells

236 Star-PAP activity is stimulated by lipid messenger phosphatid

237 Star-PAP control of the distal-specific isoform is stimulated

238 Star-PAP is a nuclear non-canonical poly(A) polymerase (PAP)

239 Star-PAP selects the distal-most site that results in the exp

240 A Star-PAP target gene, NQO1 has three poly(A) sites (PA-sites)

241 Palpha and PAPgamma) and non-canonical (Star-PAP) PAPs play diverse roles in PAS selection and gene e

242 tures in the BIK 3' UTR uniquely define Star-PAP specificity and may block canonical PAP activity tow

243 role for phosphorylation in determining Star-PAP target mRNA specificity and regulation of 3'-end pro

244 hosphorylation at the catalytic domain, Star-PAP S6 phosphorylation is insensitive to oxidative stres

245 ithin the nucleus which is required for Star-PAP nuclear retention and interaction with PIPKIalpha.

246 complex where PKCdelta is required for Star-PAP-dependent BIK expression.

247 This identifies Star-PAP as a potential drug target for the treatment of HPV-

248 c NQO1 mRNA isoforms in the presence of Star-PAP expression, and reverses molecular events of hypertr

249 PIPKIalpha controlled select subset of Star-PAP target messages by regulating Star-PAP-mRNA associat

250 sociated kinases act as coactivators of Star-PAP that regulates its activity and specificity toward m

251 In the absence of Star-PAP, treatment of cells with the chemotherapeutic drug V

252 between VP-16 treatment and the loss of Star-PAP.

253 hosphorylated residue (serine 6, S6) on Star-PAP in the zinc finger region, the domain required for P

254 ckle targeted PIPKIalpha regulated PAP (Star-PAP) controls E6 mRNA polyadenylation and expression and

255 PI4,5P(2)-regulated poly(A) polymerase Star-PAP downstream of DNA damage.

256 alpha, PI4,5P(2), and PKCdelta regulate Star-PAP control of BIK expression and induction of apoptosis

257 Star-PAP target messages by regulating Star-PAP-mRNA association.

258 We show Star-PAP-specific PAS usage regulates the expression of the e

259 timulates PKCdelta association with the Star-PAP complex where PKCdelta is required for Star-PAP-depe

260 ntial for PKCdelta interaction with the Star-PAP complex, and PKCdelta activity is directly stimulate

261 The Star-PAP-mediated APA of PTEN is essential for DNA damage-ind

262 This pathway is distinct from the Star-PAP-mediated oxidative stress pathway indicating signal-

263 perturbations of gene expression, with Star-PAP impacting lowly expressed mRNAs and long-noncoding R

264 tissue-specific elevations of the substrate PAP, up to 50-fold in liver, repressed translation, and

265 ion, allowing accumulation of its substrate, PAP, a chloroplast stress retrograde signal that regulat

266 C. elegans and, in the mouse nervous system, PAP and Kv3.1b were colocalized in subsets of neurons, i

267 dependent translation and potentially target PAP to uncapped IRES-containing RNA.

268 We demonstrate that PAP activity supplied by lipin-1, lipin-2, or lipin-3, b

269 In vivo we show that PAP is PARylated during heat shock, leading to inhibitio

270 Collectively, these data showed that PAP activity controls the expression of PSS for membrane

271 Analysis of crystal structures suggests that PAP binding restricts access to the acceptor-binding poc

272 The PAP activity shown by App1p heterologously expressed in

273 The PAP-AUC of 616 clinical samples was consistent with S-MR

274 n an equilibrium between free PNPase and the PAP I polyadenylation complex.

275 Here, we examined the PAP-mediated regulation of CHO1-encoded phosphatidylseri

276 Lipid analysis of cells lacking the PAP genes, singly or in combination, showed that Pah1p i

277 d in the fry1 papst2 mutant, which lacks the PAP-catabolizing enzyme SALT TOLERANCE 1 and PAPST2.

278 This was due to the lack of the PAP activity of lipin 1 in adipocytes after day 4 of dif

279 wild type control where the majority of the PAP I synthesized poly(A) tails were after the Rho-indep

280 metabolism in three different mutants of the PAP/SAL1 retrograde pathway.

281 2-monoacylglycerol and does not require the PAP reaction, making the role of lipin proteins in enter

282 These PAP-specific CD8(+)CTLA-4(+) suppressor T cells expresse

283 The formation of these PAP(248-286)/lipid coaggregates, which we term "messicle

284 ata suggest that triple elimination of TNAP, PAP, and NT5E is required to block AMP hydrolysis to ade

285 Moreover, our data reveal that TNAP, PAP, and NT5E are the main AMP ectonucleotidases in prim

286 d BHI-V3 plates were stratified according to PAP-AUC interpretive criteria: <0.90 (susceptible [S-MRS

287 ise with an average upstream transmission to PAP in a close to one-for-one mm Hg fashion.

288 The LTP-triggered PAP withdrawal involves NKCC1 transporters and the actin

289 position, as well as PAP activity in various PAP mutant strains, showed the essential role of PAH1 in

290 al)), volumetric distribution (VOL(AAP), VOL(PAP), and VOL(MCT)), and percentage of relative volume i

291 y pressure (PAP) >/=25 mm Hg and mean wedged PAP (PAWP) >15 mm Hg.

292 This raises the question whether PAP thereby affects the expression and activity of enzym

293 olysis, consistent with a mechanism in which PAP accumulation is toxic to tissue function independent

294 The toxicity associated with PAP I is exacerbated by the absence of either RNase T an

295 fication of various pathogens coincided with PAP in 3 of these patients.

296 row cells of a CSF2RA-deficient patient with PAP.

297 ave collected BAL samples from patients with PAP due to autoantibodies against granulocyte-macrophage

298 patients with ADA deficiency with or without PAP.

299 , resulting in a hypomorphic protein without PAP activity, but which preserved transcriptional coregu

300 A novel yeast PAP is identified as the actin patch protein encoded by